TISIDB

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Nucleus Nucleus, nucleolus
Domain	PF00929 Exonuclease PF02037 SAP domain
Function	RNA exonuclease that binds to the 3'-end of histone mRNAs and degrades them, suggesting that it plays an essential role in histone mRNA decay after replication. A 2' and 3'-hydroxyl groups at the last nucleotide of the histone 3'-end is required for efficient degradation of RNA substrates. Also able to degrade the 3'-overhangs of short interfering RNAs (siRNAs) in vitro, suggesting a possible role as regulator of RNA interference (RNAi). Requires for binding the 5'-ACCCA-3' sequence present in stem-loop structure. Able to bind other mRNAs. Required for 5.8S rRNA 3'-end processing. Also binds to 5.8s ribosomal RNA. Binds with high affinity to the stem-loop structure of replication-dependent histone pre-mRNAs.

> Gene Ontology [ TOP ]
Biological Process	GO:0000459 exonucleolytic trimming involved in rRNA processing GO:0000460 maturation of 5.8S rRNA GO:0000466 maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) GO:0000467 exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) GO:0000469 cleavage involved in rRNA processing GO:0006364 rRNA processing GO:0016072 rRNA metabolic process GO:0016458 gene silencing GO:0022613 ribonucleoprotein complex biogenesis GO:0031047 gene silencing by RNA GO:0031123 RNA 3'-end processing GO:0031125 rRNA 3'-end processing GO:0034470 ncRNA processing GO:0042254 ribosome biogenesis GO:0043628 ncRNA 3'-end processing GO:0090305 nucleic acid phosphodiester bond hydrolysis GO:0090501 RNA phosphodiester bond hydrolysis GO:0090503 RNA phosphodiester bond hydrolysis, exonucleolytic
Molecular Function	GO:0004518 nuclease activity GO:0004527 exonuclease activity GO:0008408 3'-5' exonuclease activity GO:0019843 rRNA binding GO:0036002 pre-mRNA binding GO:0043021 ribonucleoprotein complex binding GO:0043022 ribosome binding GO:0071207 histone pre-mRNA stem-loop binding
Cellular Component	GO:0071204 histone pre-mRNA 3'end processing complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-74160: Gene Expression R-HSA-6791226: Major pathway of rRNA processing in the nucleolus and cytosol R-HSA-72312: rRNA processing R-HSA-8868773: rRNA processing in the nucleus and cytosol

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ERI1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ERI1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.88; FDR: 0.04170	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -3.18; FDR: 0.00722	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ERI1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.014	0.949
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.098	0.937
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.041	0.96
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.085	0.768
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.189	0.882
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.054	0.976
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.057	0.869
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.066	0.961
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.054	0.971
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.475	0.486
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.129	0.886
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.235	0.0106

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ERI1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	7.4	0.0709
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	7.4	0.096
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ERI1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ERI1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ERI1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ERI1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ERI1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ERI1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ERI1
Name	exoribonuclease 1
Aliases	3'HEXO; enhanced RNAi three prime mRNA exonuclease homolog 1 (C.elegans); THEX1; three prime histone mRNA ex ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ERI1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ERI1